Biotech In The 1990s: What's In Store?

The first biotech company--Genentech Inc.--was casually conceived in 1976 by Herbert Boyer, a University of California, San Francisco, biologist, and Robert Swanson, a member of a West Coast venture capital firm, while they were discussing, over a beer, the uses of recombinant DNA technology. Boyer presumably was excited by the prospect that this science could be used to improve the condition of mankind and provide meaningful employ

Written byPhillip Sharp
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

The first biotech company--Genentech Inc.--was casually conceived in 1976 by Herbert Boyer, a University of California, San Francisco, biologist, and Robert Swanson, a member of a West Coast venture capital firm, while they were discussing, over a beer, the uses of recombinant DNA technology. Boyer presumably was excited by the prospect that this science could be used to improve the condition of mankind and provide meaningful employment to people.

In 1976, it was not clear how to translate the new technology into its useful roles. But Genentech provided the model for attracting venture capital, reaching agreements with pharmaceutical companies, and securing Wall Street funding. Over the past two decades, this has remained the paradigm for transferring biotechnology advances from university labs to the commercial world.

However, while the Genentech model is still valid overall, the success of biotech companies as we move through the 1990s will depend on how astutely ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies